ABL111 received FDA agreement on an accelerated approval pathway for metastatic gastric cancer as the first patient was dosed in a global phase 2 trial. The companies said ORR will support accelerated approval and phase 2 is evaluating ABL111 with nivolumab and mFOLFOX6.
NovaBridge Biosciences has enrolled the first patient in a global Phase 2 study evaluating givastomig in combination with nivolumab and chemotherapy for HER2-negative, first-line metastatic gastric cancer, with top-line results expected in 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07715747 |
A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07392892 |
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer |
RECRUITING | PHASE2/PHASE3 |
| NCT06157892 |
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer |
RECRUITING | PHASE4 |
| NCT05143970 |
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05025826 |
Study Evaluating Neurotoxicity in Patients With Metastatic Gastro Intestinal Cancer Taking Phycocare® or Placebo During Oxaliplatin Based Chemotherapy |
COMPLETED | NA |
| NCT04739202 |
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) |
COMPLETED | PHASE2 |
